Literature DB >> 32292881

Coronavirus infections: Epidemiological, clinical and immunological features and hypotheses.

Didier Raoult1, Alimuddin Zumla2,3, Franco Locatelli4, Giuseppe Ippolito5, Guido Kroemer6,7,8,9,10.   

Abstract

Coronaviruses (CoVs) are a large family of enveloped, positive-strand RNA viruses. Four human CoVs (HCoVs), the non-severe acute respiratory syndrome (SARS)-like HCoVs (namely HCoV 229E, NL63, OC43, and HKU1), are globally endemic and account for a substantial fraction of upper respiratory tract infections. Non-SARS-like CoV can occasionally produce severe diseases in frail subjects but do not cause any major (fatal) epidemics. In contrast, SARS like CoVs (namely SARS-CoV and Middle-East respiratory syndrome coronavirus, MERS-CoV) can cause intense short-lived fatal outbreaks. The current epidemic caused by the highly contagious SARS-CoV-2 and its rapid spread globally is of major concern. There is scanty knowledge on the actual pandemic potential of this new SARS-like virus. It might be speculated that SARS-CoV-2 epidemic is grossly underdiagnosed and that the infection is silently spreading across the globe with two consequences: (i) clusters of severe infections among frail subjects could haphazardly occur linked to unrecognized index cases; (ii) the current epidemic could naturally fall into a low-level endemic phase when a significant number of subjects will have developed immunity. Understanding the role of paucisymptomatic subjects and stratifying patients according to the risk of developing severe clinical presentations is pivotal for implementing reasonable measures to contain the infection and to reduce its mortality. Whilst the future evolution of this epidemic remains unpredictable, classic public health strategies must follow rational patterns. The emergence of yet another global epidemic underscores the permanent challenges that infectious diseases pose and underscores the need for global cooperation and preparedness, even during inter-epidemic periods. Copyright:
© 2020 Raoult et al.

Entities:  

Keywords:  COVID-19; Coronavirus; MERS-CoV; SARS-CoV; epidemiology; immunology; sARS-CoV-2

Year:  2020        PMID: 32292881      PMCID: PMC7146059          DOI: 10.15698/cst2020.04.216

Source DB:  PubMed          Journal:  Cell Stress        ISSN: 2523-0204


  70 in total

1.  Immunogenetics in SARS: a case-control study.

Authors:  M H L Ng; S H Cheng; K M Lau; G M Leung; U S Khoo; B C W Zee; J J Y Sung
Journal:  Hong Kong Med J       Date:  2010       Impact factor: 2.227

2.  Human coronavirus and severe acute respiratory infection in Southern Brazil.

Authors:  Hygor Trombetta; Heloisa Z Faggion; Jaqueline Leotte; Meri B Nogueira; Luine R R Vidal; Sonia M Raboni
Journal:  Pathog Glob Health       Date:  2016-05-19       Impact factor: 2.894

3.  From SARS coronavirus to novel animal and human coronaviruses.

Authors:  Kelvin K W To; Ivan F N Hung; Jasper F W Chan; Kwok-Yung Yuen
Journal:  J Thorac Dis       Date:  2013-08       Impact factor: 2.895

4.  The S proteins of human coronavirus NL63 and severe acute respiratory syndrome coronavirus bind overlapping regions of ACE2.

Authors:  Wenhui Li; Jianhua Sui; I-Chueh Huang; Jens H Kuhn; Sheli R Radoshitzky; Wayne A Marasco; Hyeryun Choe; Michael Farzan
Journal:  Virology       Date:  2007-07-12       Impact factor: 3.616

5.  Respiratory microbes present in the nasopharynx of children hospitalised with suspected pulmonary tuberculosis in Cape Town, South Africa.

Authors:  Felix S Dube; Mamadou Kaba; F J Lourens Robberts; Lemese Ah Tow; Sugnet Lubbe; Heather J Zar; Mark P Nicol
Journal:  BMC Infect Dis       Date:  2016-10-24       Impact factor: 3.090

6.  Human coronavirus circulation in the United States 2014-2017.

Authors:  Marie E Killerby; Holly M Biggs; Amber Haynes; Rebecca M Dahl; Desiree Mustaquim; Susan I Gerber; John T Watson
Journal:  J Clin Virol       Date:  2018-01-31       Impact factor: 3.168

7.  Human Coronavirus NL63 Molecular Epidemiology and Evolutionary Patterns in Rural Coastal Kenya.

Authors:  Patience K Kiyuka; Charles N Agoti; Patrick K Munywoki; Regina Njeru; Anne Bett; James R Otieno; Grieven P Otieno; Everlyn Kamau; Taane G Clark; Lia van der Hoek; Paul Kellam; D James Nokes; Matthew Cotten
Journal:  J Infect Dis       Date:  2018-05-05       Impact factor: 5.226

8.  Lack of association between HLA-A, -B and -DRB1 alleles and the development of SARS: a cohort of 95 SARS-recovered individuals in a population of Guangdong, southern China.

Authors:  P Xiong; X Zeng; M S Song; S W Jia; M H Zhong; L L Xiao; W Lan; C Cai; X W Wu; F L Gong; W Wang
Journal:  Int J Immunogenet       Date:  2008-02       Impact factor: 1.466

9.  Is COVID-19 receiving ADE from other coronaviruses?

Authors:  Jason A Tetro
Journal:  Microbes Infect       Date:  2020-02-22       Impact factor: 2.700

10.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention.

Authors:  Zunyou Wu; Jennifer M McGoogan
Journal:  JAMA       Date:  2020-04-07       Impact factor: 56.272

View more
  102 in total

Review 1.  Interferon therapy in patients with SARS, MERS, and COVID-19: A systematic review and meta-analysis of clinical studies.

Authors:  Kiarash Saleki; Shakila Yaribash; Mohammad Banazadeh; Ehsan Hajihosseinlou; Mahdi Gouravani; Amene Saghazadeh; Nima Rezaei
Journal:  Eur J Pharmacol       Date:  2021-06-12       Impact factor: 4.432

2.  A Comparative NLP-Based Study on the Current Trends and Future Directions in COVID-19 Research.

Authors:  Priyankar Bose; Satyaki Roy; Preetam Ghosh
Journal:  IEEE Access       Date:  2021-05-20       Impact factor: 3.367

Review 3.  COVID-19: molecular pathophysiology, genetic evolution and prospective therapeutics-a review.

Authors:  C T Dhanya Raj; Dinesh Kumar Kandaswamy; Ravi Chandra Sekhara Reddy Danduga; Raju Rajasabapathy; Rathinam Arthur James
Journal:  Arch Microbiol       Date:  2021-02-08       Impact factor: 2.552

Review 4.  Current understanding on molecular drug targets and emerging treatment strategy for novel coronavirus-19.

Authors:  Khadga Raj; Karamjeet Kaur; G D Gupta; Shamsher Singh
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2021-05-07       Impact factor: 3.000

5.  Dental Professional's Knowledge, Preventive Awareness and Attitude Towards COVID-19 in Saudi Arabia: A Cross-Sectional Survey.

Authors:  Rayyan Abdallah Alwazzan; Mohammad A Baseer; Osamah Mohammed ALMugeiren; Navin Anand Ingle
Journal:  Risk Manag Healthc Policy       Date:  2021-06-01

6.  Development and validation of a machine learning model to predict mortality risk in patients with COVID-19.

Authors:  Anna Stachel; Kwesi Daniel; Dan Ding; Fritz Francois; Michael Phillips; Jennifer Lighter
Journal:  BMJ Health Care Inform       Date:  2021-05

7.  Will SARS-CoV-2 Become Just Another Seasonal Coronavirus?

Authors:  Alexander B Beams; Rebecca Bateman; Frederick R Adler
Journal:  Viruses       Date:  2021-05-07       Impact factor: 5.048

Review 8.  COVID-19 in Relation to Hyperglycemia and Diabetes Mellitus.

Authors:  Hayder M Al-Kuraishy; Ali I Al-Gareeb; M Alblihed; Susana G Guerreiro; Natália Cruz-Martins; Gaber El-Saber Batiha
Journal:  Front Cardiovasc Med       Date:  2021-05-20

Review 9.  Revolutionizing polymer-based nanoparticle-linked vaccines for targeting respiratory viruses: A perspective.

Authors:  Yinghan Chan; Sin Wi Ng; Sachin Kumar Singh; Monica Gulati; Gaurav Gupta; Sushil Kumar Chaudhary; Goh Bey Hing; Trudi Collet; Ronan MacLoughlin; Raimar Löbenberg; Brian G Oliver; Dinesh Kumar Chellappan; Kamal Dua
Journal:  Life Sci       Date:  2021-06-24       Impact factor: 6.780

Review 10.  Computational Lock and Key and Dynamic Trajectory Analysis of Natural Biophors Against COVID-19 Spike Protein to Identify Effective Lead Molecules.

Authors:  Irfan Navabshan; Balasubramaniyan Sakthivel; Rajesh Pandiyan; Mariya Gover Antoniraj; Selvakumar Dharmaraj; Veeramuthu Ashokkumar; Kuan Shiong Khoo; Kit Wayne Chew; Abimanyu Sugumaran; Pau Loke Show
Journal:  Mol Biotechnol       Date:  2021-06-22       Impact factor: 2.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.